Group 1: Company Overview and Market Position - Beirui Gene has been engaged in the gene sequencing industry for over 15 years, focusing on reproductive health, genetic disease testing, and technology services [2] - The company has accumulated a vast amount of diagnostic data, ranging from hundreds of megabytes to tens of gigabytes per sample, establishing a strong foundation for data processing [2] - The gene testing industry is transitioning from an algorithmic era to an intelligent era represented by large models, with significant attention on global market changes [2] Group 2: Data Accumulation and Infrastructure - The gene testing data center has surpassed the petabyte (PB) level in data storage, with over 100 million data points ready for internal research and analysis [3] - The company has built a comprehensive medical knowledge graph with over hundreds of millions of relationships and nearly 100 million nodes, ensuring high-quality and usable data [3] - The public data center and literature data center have also accumulated over 100 million data points combined, enriching the data dimensions available for analysis [3] Group 3: AI and Intelligent Tools - Beirui Gene has developed multiple proprietary algorithms and applications based on open-source large models, including genetic disease prediction and intelligent literature retrieval algorithms [4] - The company provides consulting services to over 2,000 hospitals and research institutions, enhancing clinical data interpretation efficiency [4] - The integration of AI algorithms has significantly improved report interpretation efficiency, increasing the output capacity of clinical reports [5] Group 4: Future Applications and Strategic Plans - The company plans to develop AI diagnostic, chronic disease management, and medical service segments for B-end clients, while also launching platforms for C-end clients [5] - Beirui Gene aims to accelerate the digital transformation of hospitals by promoting its intelligent products in alignment with national health strategies [2] - The company is strategically collaborating with major medical institutions to develop AI-driven big data solutions for molecular diagnosis and beyond [6] Group 5: Data Management and Security - The company has established unified data standards to address the challenges of data integration and ensure data accuracy and reliability [12] - A comprehensive data development framework has been created to assist clients in building frequency and variant databases, enhancing customer satisfaction and market competitiveness [14] - Data security measures include professional anonymization of private data, ensuring compliance while maximizing data utility [14]

成都市贝瑞和康基因技术股份有限公司 关于股票交易异常波动的公告 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-003 5、股票异常波动期间，控股股东、实际控制人及其一致行动人未买卖公司 股票； 6、公司不存在违反公平信息披露的情形。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"、"本公司"） 股票于2025年2月6日、2025年2月7日、2025年2月10日连续3个交易日收盘价涨 幅偏离值累计超过20%。根据《深圳证券交易所交易规则》的相关规定，属于 股票交易异常波动。 二、公司关注并核实的相关情况 根据相关规定的要求，公司及时进行了核查，并向公司控股股东和实际控制 人及其一致行动人进行了问询，现对有关核实情况说明如下： 1、公司前期所披露的信息，不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息； 3、公司已披露的经营情况、内外部经营环境未发生重大变化； 4、公司、控股股东和实际控制人及 ...

2025 年 2 月 5 日，公司通过淘宝网司法拍卖网络平台查询获悉，因案外人对拍 卖财产提出确有理由的异议，本场司法拍卖已撤回。 公司将持续关注本场司法拍卖及相关事项的进展情况，按照法律法规要求及时 履行信息披露义务，敬请投资者注意投资风险。 特此公告。 成都市贝瑞和康基因技术股份有限公司董事会 2025年2月5日 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-002 成都市贝瑞和康基因技术股份有限公司 关于控股股东所持公司部分股份司法拍卖撤回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 公司于 2024 年 12 月 28 日披露了《关于控股股东所持公司部分股份将被司法拍 卖的提示性公告》（公告编号：2024-056），成渝金融法院拟将公司控股股东高扬先 生持有的公司 16,600,000 股股票于 2025 年 2 月 6 日 10：00 时起至 2025 年 2 月 7 日 10：00 时止在淘宝网司法拍卖网络平台上进行公开拍卖（以下简称"本场司法拍卖"）。 1 ...

Financial Performance Expectations - The company expects a net loss attributable to shareholders of between 170 million and 250 million yuan for the fiscal year 2024, a reduction in loss of 41.48% to 60.21% compared to a loss of 427.2 million yuan in the same period last year [2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 168 million to 248 million yuan, representing a decrease in loss of 40.51% to 59.70% compared to a loss of 416.8 million yuan last year [2]. - Basic earnings per share are expected to be a loss of 0.48 to 0.71 yuan per share, compared to a loss of 1.21 yuan per share in the previous year [2]. Revenue and Profitability Outlook - The company anticipates a slight decline in total operating revenue for the year, while the overall gross profit margin is expected to increase slightly [4]. Strategic Focus and Operational Improvements - The company is focusing on its core business and tightening operational strategies to enhance its competitive edge and improve sustainable operational capabilities [4]. - The company has conducted a comprehensive review and impairment testing of various assets, which has significantly impacted the net profit for the reporting period [4]. Financial Reporting and Audit Status - The financial data provided is preliminary and has not been audited, with the final figures to be disclosed in the 2024 annual report [5].

Core Viewpoint - Berry Genomics has announced the successful delivery and testing of the Vega platform, a desktop long-read sequencing platform developed in collaboration with Pacific Biosciences, aimed at enhancing genetic testing solutions for clinical needs in China and abroad [1][2]. Group 1: Product Development and Features - The Vega platform integrates the capabilities of PacBio's Revio system into a compact, medium-throughput desktop platform, utilizing HiFi technology to ensure data accuracy and turnaround time [1][2]. - The platform is designed to provide comprehensive solutions for various applications, including targeted sequencing, RNA sequencing, and small genome sequencing [1][2]. - The introduction of the Vega platform significantly improves the economic viability and accessibility of HiFi long-read sequencing, enabling more researchers to utilize this technology [2][3]. Group 2: Market Strategy and Clinical Applications - Berry Genomics plans to accelerate the development of customized genetic testing solutions based on the Vega platform to meet the growing clinical demands in both domestic and international markets [2][4]. - The company aims to enhance its market promotion efforts to facilitate the sales of the Vega platform, transitioning its business model from genetic testing services to upstream equipment and reagent sales [4][5]. - The Vega CNDx model is being developed to align with the characteristics of the Chinese population and clinical needs, contributing to the localization of sequencing platforms [5]. Group 3: Collaboration and Industry Position - PacBio's COO highlighted Berry Genomics' critical role in the development of the Vega platform, emphasizing the importance of their early testing and data accumulation from the Sequel II system [4]. - The collaboration is expected to deepen, leveraging Berry Genomics' extensive experience in the Chinese clinical market to tailor the Vega platform to meet local demands [4]. - Berry Genomics is positioning itself in the upstream core equipment market, recognizing sequencing instruments as a key component with high industry barriers [4].

Partnership Establishment - The partnership aims to raise a total fund size of RMB 134 million [1] - Berry Genomics' wholly-owned subsidiary Berry Health, together with Shanghai Zhikai Asset Management Co Ltd, Fuzhou New Venture Capital Co Ltd, Shanghai Runda Medical Technology Co Ltd, and Shanghai Fukairuikang Enterprise Management Consulting Partnership (Limited Partnership), have signed a partnership agreement to establish Fuzhou New Venture Zhikai Ruikang Venture Capital Fund Partnership (Limited Partnership) [2]

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-057 成都市贝瑞和康基因技术股份有限公司 关于与专业投资机构共同投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、投资概述 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）全资子公司福建 贝瑞和康基因技术有限公司（以下简称"贝瑞和康"）与上海致凯资产管理有限公 司、福州新投创业投资有限公司、上海润达医疗科技股份有限公司、上海福凯瑞康 企业管理咨询合伙企业（有限合伙）共同签署《福州新投致凯瑞康创业投资基金合 伙企业（有限合伙）合伙协议》（以下简称"合伙协议"），共同投资设立福州新 投致凯瑞康创业投资基金合伙企业（有限合伙）（以下简称"合伙企业"），合伙 企业目标募资规模为人民币13,400万元，其中公司作为有限合伙人认缴出资2,680 万元，占合伙企业出资总额的20.00%。 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指 引第7号——交易与关联交易》《公司章程》等相关规定，本次对外投资事项无需 提交公司董事会及股东大会审议。 公司住所：上海市黄浦区茂名南 ...

关于控股股东所持公司部分股份将被司法拍卖的提示性公告 证券代码：000710 证券简称：贝瑞基因 公告编号：2024-056 成都市贝瑞和康基因技术股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次拍卖标的物为公司控股股东高扬先生持有的本公司 16,600,000 股股票， 占其持有公司股份的比例为 51.89%，占公司总股本的比例为 4.70%。上述将被司法 拍卖的股份为无限售流通股，均已被质押并司法再冻结。 2、目前该拍卖事项尚在公示阶段，后续可能涉及竞拍、缴款、法院执行法定程 序、股权变更、过户等环节，存在一定的不确定性，公司将根据进展情况，依法履行 相应的信息披露义务。本次拍卖事项存在导致公司控股股东发生变更的风险，敬请广 大投资者注意投资风险。 3、公司目前生产经营情况正常，该事项未对公司的生产经营及财务状况产生重 大不利影响，未对公司治理结构产生重大不利影响。 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"或"公司"）于 近日收到控股股东高扬先生发送的《成渝金融法院网络司法拍卖事项通知书》并通过 司法拍卖网 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-055 成都市贝瑞和康基因技术股份有限公司 关于控股股东股份被司法再冻结的公告 截至本公告日，上述股东及其一致行动人所持股份累计被司法冻结或司法标 记情况如下： 1、控股股东高扬先生及其一致行动人侯颖女士累计被司法冻结、司法再冻 结或司法标记股份数量占其所持公司股份数量比例达到 100%，请投资者 注意相关风险。 2、控股股东及其一致行动人被冻结的股份出现平仓风险或被强制过户风险， 请投资者注意相关风险。 | | | | | | 合计占 | 合计占 | | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 持股数量 | 持股比 | 累计被冻结数量（股） | 累计被标记 | 其所持 | 公司总 | | 称 | （股） | 例 | | 数量（股） | 股份比 | 股本比 | | | | | | | 例 | 例 | | 高扬 | 31,988,723 | 9.05% | 31,988,723 | 0 | 100% | 9.05% | | 侯颖 | 14,920,736 | 4.22% | 7,703,4 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-054 成都市贝瑞和康基因技术股份有限公司 关于控股股东被动减持实施期限届满暨实施结果的公告 控股股东高扬先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 1 股东 名称 股份性质 本次被动减持前持有股份 本次被动减持后持有股份 股数 （股） 占总股本比 例（%） 股数 （股） 占总股本比 例（%） 高扬 合计持有股份 35,522,872 10.0483 31,988,723 9.0486 其中：无限售条件股份 260,000 0.0736 5,346,569 1.5124 2、股东本次被动减持前后持股情况 | 有限售条件股份 35,262,872 | | --- | | 9.9747 | | 26,642,154 7.5362 | 截至本公告日，本次被动减持事项不存在违反高扬先生此前已披露的持股意 向、承诺等情形。 特别提示： 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）于2024年7月 10日披露了《关于控股股东被动减持股份的预 ...